Publications
Optimizing reperfusion therapy in acute ST-elevation myocardial infarction by a pharmaco-invasive treatment approach in a well-organized network.
Huber K et al. Eur. Heart J. 2011
3rd Department of Internal Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Montleartstrasse 37, A-1160 Vienna, Austria.
...
Oncostatin M and IL-6 induce u-PA and VEGF in prostate cancer cells and correlate in vivo.
Weiss TW et al. Anticancer Res. 2011
Third Medical Department for Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria. thomas.weiss(0)meduniwien.ac.at
...
Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents.
Höchtl T et al. Fundam Clin Pharmacol 2011
3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Montleartstrasse 37, A-1160 Vienna, Austria Department of Pharmacology and Clinical Pharmacology, Heinrich-Heine University, Düsseldorf, Germany.
Antiplatelet therapy is obligatory in patients with coronary artery disease (CAD) both in acute coronary syndromes (ACS) and in secondary prevention. Aspirin in combination with clopidogrel has been recommended as the main therapeutic regimen for man...
Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques.
Demyanets S et al. Arterioscler. Thromb. Vasc. Biol. 2011
Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
OBJECTIVE: Interleukin (IL)-33 is the most recently described member of the IL-1 family of cytokines and it is a ligand of the ST2 receptor. While the effects of IL-33 on the immune system have been extensively studied, the properties of this cytokin...
Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure.
Tentzeris I et al. Eur. J. Heart Fail. 2011
3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, Montleartstrasse 37, Vienna, Austria. i_tentzeris(0)gmx.net
...
Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
Freynhofer MK et al. Thromb. Haemost. 2011
3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, A-1160, Vienna, Austria. matthias.freynhofer(0)meduniwien.ac.at
Reduced antiplatelet effect of clopidogrel assessed with multiple electrode aggregometry (MEA) and vasodilator stimulated phosphoprotein-phosphorylation (VASP-P) assay has been proven to predict major adverse cardiovascular events (MACE) after corona...
Platelet-monocyte cross talk and tissue factor expression in stable angina vs. unstable angina/non ST-elevation myocardial infarction.
Kopp CW et al. Platelets 2011
Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. christoph.kopp(0)meduniwien.ac.at
Tissue factor (TF), the major procoagulant in vivo, is usually absent from blood cells. However, since both monocyte TF (MoTF) expression and platelet activation are present in acute coronary syndrome we hypothesized that MoTF expression may in part ...
Platelet function variability and non-genetic causes.
Tentzeris I et al. Thromb. Haemost. 2011
3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Montleartstrasse 37, Vienna, Austria.
Dual antiplatelet therapy (DAPT) has been established for the treatment of coronary artery disease, especially in and after acute coronary syndromes, and after coronary interventions. Data suggest that a significant percentage of individuals treated ...
Genetic variability in response to clopidogrel therapy and its clinical implications.
Yukhanyan L et al. Thromb. Haemost. 2011
3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Montleartstrasse 37, Vienna, Austria.
This article concentrates on individual genetic differences responsible for variations of action of clopidogrel, which have been found to be partially responsible for increased cardiovascular events in patients with coronary artery disease under dual...
Inflammation and cardiac outcome.
Hohensinner PJ et al. Curr. Opin. Infect. Dis. 2011
Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. philipp.hohensinner(0)meduniwien.ac.at
...
High soluble Fas and soluble Fas Ligand serum levels before stent implantation are protective against restenosis.
Katsaros KM et al. Thromb. Haemost. 2011
Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Percutaneous coronary intervention (PCI) represents the most important treatment of coronary artery stenosis today. But instent restenosis (ISR) is a limitation for the outcome. Fas and Fas Ligand have been implicated in apoptosis and vessel wall inf...
Drug-eluting introducer sheath prevents local peripheral complications: pre-clinical evaluation of nitric oxide-coated sheath.
Hemetsberger R et al. JACC Cardiovasc Interv 2011
Department of Cardiology, Medical University of Vienna, Vienna, Austria.
...
New anticoagulant agents in acute coronary syndromes.
Höchtl T et al. Heart 2011
3rd Medical Department, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria.
...
Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2- and STAT1/STAT3-dependent pathways and is attenuated by interferon-γ
Demyanets S et al. Basic research in cardiology 2010
Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
The pleiotropic cytokine oncostatin M (OSM), a member of the glycoprotein (gp)130 ligand family, plays a key role in inflammation and cardiovascular disease. As inflammation precedes and accompanies pathological angiogenesis, we investigated the effe...
Complement in atherosclerosis: friend or foe?
Speidl WS et al. J. Thromb. Haemost. 2011
Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Atherosclerosis is a chronic inflammatory disease and the complement system plays a central role in innate immunity. Increasing evidence exists that the complement system is activated within atherosclerotic plaques. However, the role of complement in...
Levels of von Willebrand factor and ADAMTS13 determine clinical outcome after cardioversion for atrial fibrillation.
Freynhofer MK et al. Thromb. Haemost. 2011
3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, Vienna, Austria. matthias.freynhofer(0)meduniwien.ac.at
Von Willebrand factor (vWF) plays an essential role in platelet adhesion and thrombus formation. Patients with atrial fibrillation (AF) exhibit higher plasma vWF and lower ADAMTS13 antigen levels compared to controls. Little is known about vWF and AD...
Diabetic specific aspects in antithrombotic therapy in patients with coronary artery disease.
Farhan S et al. Minerva Med. 2010
rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, Vienna, Austria - serdar.farhan(0)wienkav.at.
The use of combined antithrombotic medication in optimal dosages is mandatory for diabetic patients. Moreover, specific antiplatelet therapy in DM has been shown to reduce early and late atherothrombotic events in patients referred for elective and a...
Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
Tentzeris I et al. Thrombosis and haemostasis 2010
Dr. Ioannis Tentzeris, 3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, Montleartstrasse 37, Vienna, A- 1160 Austria, Tel.: +43 1 491502301, Fax: +43 1 49150 2309, E-mail: i_tentzeris(0)gmx.net.
The aim of the study was to evaluate the effect of the concomitant treatment with proton-pump inhibitors (PPIs) and clopidogrel on the incidence of stent thrombosis, acute coronary syndrome (ACS) and death in patients who underwent percutaneous coron...
Association between smoking and presence of mycoplasma pneumoniae in circulating leukocytes.
Weiss TW et al. Swiss Med Wkly 2010
Department of Cardiology, Medical Division, Oslo University Hospital, Norway. thomas.weiss(0)meduniwien.ac.at
...
Long-term outcome after drug-eluting stent implantation in comparison with bare metal stents: a single centre experience.
Tentzeris I et al. Clinical research in cardiology : official journal of the German Cardiac Society 2010
3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, Montleartstrasse 37, 1160, Vienna, Austria, i_tentzeris(0)gmx.net.
BACKGROUND: The aim of our study was to evaluate the effect of drug-eluting stents (DES) compared with bare-metal stents (BMS) on all-cause mortality and target vessel revascularization (TVR) in a "real-world" clinical setting. METHODS AND ...
Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure.
Richter B et al. Atherosclerosis 2010
Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
OBJECTIVE: To assess the prognostic value of the pro-apoptotic, but also cell growth-inducing molecule soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) in heart failure (HF). METHODS: We assayed sTWEAK levels in 351 patients with...
Optimization of drug-eluting balloon use for safety and efficacy: evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coronary arteries.
Pósa A et al. Catheter Cardiovasc Interv 2010
Department of Cardiology, Medical University of Vienna, Austria.
...
The complement component C5a is present in human coronary lesions in vivo and induces the expression of MMP-1 and MMP-9 in human macrophages in vitro.
Speidl WS et al. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2010
*Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria;The Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria;The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York, USA;Department of Cardiology/Heart Center, University of Bonn, Germany; and||Third Department of Medicine (Cardiology and Emergency Medicine), Wilhelminenspital, Vienna, Austria.
The complement component C5a is formed during activation of the complement cascade and exerts chemotactic and proinflammatory effects. Macrophages, which are localized in the rupture-prone shoulder regions of coronary plaques, are thought to play a m...
The complement component C5a is present in human coronary lesions in vivo and induces the expression of MMP-1 and MMP-9 in human macrophages in vitro.
Speidl WS et al. FASEB J. 2011
Department of Internal Medicine II, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
The complement component C5a is formed during activation of the complement cascade and exerts chemotactic and proinflammatory effects. Macrophages, which are localized in the rupture-prone shoulder regions of coronary plaques, are thought to play a m...
Prognostic Value of Pigment Epithelium-Derived Factor in Advanced Heart Failure Patients.
Rychli K et al. Chest 2010
From the *Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, and.
Abstract OBJECTIVE: While angiogenesis, the formation of new blood vessels from pre-existing vessels, may be beneficial in restoring the failing myocardium, apoptosis may contribute to progression of heart failure (HF). We investigated the role of pi...
Page 1 of 5
«StartPrev12345NextEnd»Members Area
Browser Support
 |
 |
 |
Screen Resolution: 1024x768
Search
Recent Publications
- Optimizing reperfusion therapy in acute ST-elevation myocardial infarction by a pharmaco-invasive treatment approach in a well-organized network.
- Oncostatin M and IL-6 induce u-PA and VEGF in prostate cancer cells and correlate in vivo.
- Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents.
- Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques.
- Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure.